Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Post Ocular Surgical Inflammation and Pain Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The RESTORE Study, A Randomized, Controlled, Masked (Reading Center) Prospective Study

NCT04396990
View directory record Official record
Conditions
Refractive Surgery
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone
Drug
Lead sponsor
Vance Thompson Vision
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

"A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation"

NCT04781335
View directory record Official record
Conditions
Cataract
Interventions
Dexycu, Standard of Care post operative eye drops (steroid, antibiotic, NSAID)
Drug
Lead sponsor
The Eye Institute of West Florida
Other
Eligibility
40 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Largo, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Jul 22, 2026, 3:58 PM EDT
Not listed Phase 4 Interventional

Dextenza Within Upper Lid Canaliculus Compared With Lower Lid Canaliculus Following Bilateral Cataract Extraction Surgery With PCIOL.

NCT04592081
View directory record Official record
Conditions
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
Interventions
Dextenza 0.4Mg Ophthalmic Insert
Drug
Lead sponsor
Kerry Assil, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Results available

Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract

NCT03496467
View directory record Official record
Conditions
Pain, Inflammation
Interventions
Nepafenac PPDS, Placebo PPDS
Combination Product
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
22 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Edgewood, Kentucky • Garden City, New York • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Jul 22, 2026, 3:58 PM EDT
Terminated Phase 1 Interventional Results available

A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery

NCT01605942
View directory record Official record
Conditions
Cataract
Interventions
Dexamethasone Drug Delivery System, Placebo Drug Delivery System
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Jul 22, 2026, 3:58 PM EDT
Terminated Phase 3 Interventional

Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery

NCT06128369
View directory record Official record
Conditions
Inflammation Eye, Pain, Postoperative, Cataract
Interventions
Dexamethasone Ophthalmic Suspension, Vehicle of OCS-01
Drug · Other
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
12
States / cities
Inglewood, California • Morrow, Georgia • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

NCT02793817
View directory record Official record
Conditions
Post Surgical Ocular Inflammation and Pain
Interventions
KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
35
States / cities
Chandler, Arizona • Phoenix, Arizona • Artesia, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

NCT04810962
View directory record Official record
Conditions
Ocular Inflammation and Pain After Cataract Surgery
Interventions
APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
31
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Results available

Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects

NCT04324359
View directory record Official record
Conditions
Post-surgical Ocular Inflammation, Post-surgical Ocular Pain
Interventions
SURF-201, Placebo
Drug
Lead sponsor
Surface Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Hemet, California • Murrieta, California • Brooksville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery

NCT04739709
View directory record Official record
Conditions
Ocular Inflammation and Pain
Interventions
APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
34
States / cities
Scottsdale, Arizona • Glendale, California • Hemet, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Jul 22, 2026, 3:58 PM EDT
Recruiting Phase 4 Interventional

Dextenza in the Post-op Management of Vitreoretinal Surgeries

NCT04371445
View directory record Official record
Conditions
Vitreoretinal Surgery, Ocular Inflammation, Post-operative Pain, Post-Operative Inflammation
Interventions
Dexamethasone Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery

NCT04089735
View directory record Official record
Conditions
Ocular Inflammation and Pain After Cataract Surgery
Interventions
APP13007, 0.05%, APP13007, 0.1%, APP13007 Placebo, 0.05%, APP13007 Placebo, 0.1%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Inglewood, California • Rancho Cordova, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Results available

OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

NCT04130802
View directory record Official record
Conditions
Inflammation Corneal, Pain, Postoperative
Interventions
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL, Placebo
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Petaluma, California • Roseburg, Oregon • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dextenza for Post-operative Treatment of Pterygium

NCT04351737
View directory record Official record
Conditions
Pterygium of Both Eyes
Interventions
Intracanalicular Dexamethasone, (0.4 mg) Insert, Prednisolone Acetate
Drug
Lead sponsor
Brandon Eye Associates, PA
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Brandon, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Results available

Confirmatory Study Nepafenac 0.3%

NCT01109173
View directory record Official record
Conditions
Cataract
Interventions
Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Ophthalmic Suspension 0.3% Vehicle, NEVANAC Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
2,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain

NCT02508337
View directory record Official record
Conditions
Inflammation, Pain, Cataract
Interventions
XG-102, Placebo
Drug
Lead sponsor
Xigen SA
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of TRS01 in Participants With Post-surgical Ocular Inflammation

NCT04222725
View directory record Official record
Conditions
Post Surgical Ocular Inflammation
Interventions
TRS01 eye drops, Placebo eye drops
Drug
Lead sponsor
Tarsier Pharma
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Inglewood, California • Petaluma, California • Washington, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

NCT02235272
View directory record Official record
Conditions
Inflammation, Pain, Cataract
Interventions
XG-102, Placebo
Drug
Lead sponsor
Xigen SA
Industry
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 4 Interventional

Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery

NCT04316936
View directory record Official record
Conditions
Cataract Surgery
Interventions
Omidria, Dextenza (dexamethasone ophthalmic insert) 0.4mg, Dexycu, 9% Intraocular Suspension, Prednisolone Acetate 1%
Drug
Lead sponsor
Silverstein Eye Centers
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%

NCT04273282
View directory record Official record
Conditions
Cataract
Interventions
Dexycu intracameral dexamethasone, Prednisolone Acetate
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Laguna Hills, California • Garden City, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery

NCT01666210
View directory record Official record
Conditions
Ocular Inflammation and Pain
Interventions
OTX-DP (Dexamethasone punctum plug), Placebo Vehicle Punctum Plug
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Hoffman Estates, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery

NCT02034019
View directory record Official record
Conditions
Post Ocular Surgical Inflammation and Pain
Interventions
Dexamethasone, Punctum Plug
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Jul 22, 2026, 3:58 PM EDT